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Two commonly encountered bottlenecks in the structure determination of a
protein by X-ray crystallography are screening for conditions that give high-
quality crystals and, in the case of novel structures, finding derivatization
conditions for experimental phasing. In this study, the phasing molecule
5-amino-2,4,6-triiodoisophthalic acid (I3C) was added to a random microseed
matrix screen to generate high-quality crystals derivatized with I3C in a single
optimization experiment. I3C, often referred to as the magic triangle, contains
an aromatic ring scaffold with three bound I atoms. This approach was applied to
efficiently phase the structures of hen egg-white lysozyme and the N-terminal
domain of the Orf11 protein from Staphylococcus phage P68 (Orf11 NTD) using
SAD phasing. The structure of Orf11 NTD suggests that it may play a role as a
virion-associated lysin or endolysin.
1. Introduction
X-ray crystallography is commonly used to determine the
three-dimensional structures of proteins, with over 148 000
structures deposited in the Protein Data Bank (PDB) as of
February 2019 (Burley et al., 2019). However, there are many
bottlenecks in successful structure determination. For a
protein for which no X-ray crystal structure exists, the
conditions that will give rise to crystals are not known a priori.
Many crystallization conditions are screened to find one that
provides diffracting crystals. However, the large number of
factors that affect crystallization, including protein concen-
tration, precipitant, buffer, salt concentrations and tempera-
ture, make an exhaustive screening expensive and laborious
(Jancarik & Kim, 1991). Sparse-matrix screens are often used
to efficiently find crystallization conditions (Jancarik & Kim,
1991). Sparse matrix is a data-mining approach that chooses
crystallization conditions based on known and published
crystallization conditions. It can be generalized or tailored to
the macromolecule, for example membrane proteins or DNA-
binding proteins. Many sparse-matrix screens are readily
available commercially. Ireton & Stoddard (2004) pioneered
the microseed matrix screening (MMS) technique of trans-
ferring crystal seeds from existing crystals to new crystal-
lization conditions to create new conditions in which crystals
can grow. D’Arcy et al. (2007) further developed the technique
for use with random crystallization screens, such as the sparse-
matrix screens already described. This approach was named
random microseed matrix screening (rMMS) and was found
ISSN 2059-7983
to be an effective method for increasing the number of hit
crystallization conditions. In many cases, improved diffraction-
quality crystals could be obtained.
A protein structure can only be obtained using X-ray
crystallography if the phase problem can be solved. This
presents another bottleneck. If a suitable search model is
available through a homologous structure, the phase problem
can be solved by molecular replacement (MR; Rossmann,
1990; McCoy et al., 2007; Bibby et al., 2012). However, many
protein targets being studied do not have a suitable template
and require experimental phasing.
Several experimental phasing techniques have been devel-
oped. The traditional phasing method is isomorphous
replacement, which involves soaking crystals in solutions
containing heavy atoms such as lead, mercury or uranium.
Another phasing technique is anomalous dispersion at a single
wavelength (SAD; Wang, 1985) or multiple wavelengths
(MAD; Hendrickson, 1991). The anomalous dispersion tech-
nique requires atoms to be incorporated into the crystal lattice
that scatter anomalously at the wavelengths available at the
X-ray source. These can be incorporated through soaks or co-
crystallization with heavy-atom solutions, chemical modifica-
tion (for example selenium modification of nucleic acids) or
labeling during protein expression (selenomethonine and
selenocysteine). The theories of isomorphous replacement
and anomalous dispersion are described in Taylor (2010).
Suitable compounds and conditions for heavy-atom derivati-
zation are found empirically by screening. This process can be
very laborious, although some rational approaches have been
devised to guide the screening process (Lu & Sun, 2014).
Beck et al. (2008, 2010) synthesized the ‘magic triangle’
(I3C) and ‘MAD triangle’ (B3C) compounds specifically for
phasing, showing that they could phase several model proteins
(Fig. 1). Currently, there are 19 structures in the Protein Data
Bank that have been solved using I3C. The triangular
arrangement of anomalous scatterers can easily be identified
in the substructure. The two carboxylate groups and one
amino group can interact with the protein through hydrogen
bonding to either the protein backbone or to side chains to
facilitate more specific binding.
In this study, we incorporated I3C into an rMMS screen to
increase the chance of obtaining diffraction-quality crystals
while simultaneously incorporating heavy atoms into the
crystal for experimental phase determination. This method
aims to overcome the two identified bottlenecks in structure
determination of novel targets in one step. We demonstrated
this technique using hen egg-white lysozyme (HEWL) and the
N-terminal domain of Orf11 from Staphylococcus bacterio-
phage P68 (Orf11 NTD). Orf11 NTD is a good example of a
target that does not have a suitable template in the PDB to use
for MR and that did not produce sufficient hit conditions in an
initial screen. Our devised method very quickly gave diffrac-
tion-quality crystals that were already derivatized with a
heavy-atom compound and allowed the structure to be solved.
2. Methods
2.1. Crystallization of HEWL
HEWL was commercially acquired from Sigma–Aldrich
(catalog No. L6876) as a lyophilized powder. The powder was
dissolved in TBS (50 mM Tris–HCl pH 7.6, 150 mM NaCl) to a
final concentration of 30 mg ml1 as determined using UV
absorbance at 280 nm.
Lysozyme crystals were grown via hanging-drop vapor
diffusion. 1 ml protein solution was mixed with 1 ml reservoir
solution [0.2 M ammonium tartrate dibasic pH 7.0, 20%(w/v)
polyethylene glycol 3350] and equilibrated against 500 ml
reservoir solution. The crystals obtained were crushed to
generate an rMMS seed stock as described by D’Arcy et al.
(2007).
Sitting-drop vapor-diffusion crystallization screening of
HEWL was performed in 96-well Intelli-Plates (Art Robbins)
using the commercial Index HT screen (Hampton Research).
Four crystallization screens were carried out corresponding to
lysozyme without seeds or I3C, lysozyme with seeds, lysozyme
with I3C, and lysozyme with seeds and I3C.
For screens containing I3C, 1 M I3C stock was directly
added to the protein to give a final concentration of 20 mM
I3C. Sitting-drop vapor-diffusion trays were set up with the
I3C-containing protein stock. 1 ml protein solution was added
to 1 ml reservoir solution and 0.1 ml seed stock and equili-
brated over 75 ml reservoir solution.
A seeded crystal from condition C6 of Index HT grown in
the presence of I3C showed suitable diffraction. These crystals
appeared after three days and reached their maximum size
within two weeks. The size of the crystals was estimated to be
150 mm. Crystals were mounted on cryoloops (Hampton
Research), passed through Paratone (Hampton Research) for
cryoprotection and flash-cooled in liquid nitrogen for data
collection (Teng, 1990).
2.2. Data collection, structure solution and refinement of
HEWL
A 1.87 Å resolution SAD data set was collected at a
wavelength of 1.459 Å using an ADSC Quantum 210r CCD
detector on the macromolecular beamline MX1 at the
Australian Synchrotron (McPhillips et al., 2002). This wave-
length allows iodine to have a large anomalous signal (f 00 =
6.3 e and f 0 = 0.13 e). 360 diffraction images with 1 oscil-
lation width were collected at a crystal-to-detector distance of
120 mm. The diffraction data from two crystals were processed
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Figure 1
Chemical structures of I3C (5-amino-2,4,6-triiodoisophthalic acid) and
B3C (5-amino-2,4,6-tribromoisophthalic acid).
using XDS (Kabsch, 2010) and combined and scaled using
AIMLESS (Evans & Murshudov, 2013) (Table 1).
The structure was solved using the SAD protocol of Auto-
Rickshaw, the EMBL Hamburg automated crystal structure-
determination platform (Panjikar et al., 2005). The diffraction
data processed using AIMLESS (Evans & Murshudov, 2013)
were used as input. FA values were calculated using SHELXC
(Sheldrick, 2015). Based on an initial analysis of the data, the
maximum resolution for substructure determination and
initial phase calculation was set to 1.8 Å. 17 potential heavy-
atom sites out of the maximum number of 20 heavy atoms
requested were found using SHELXD (Schneider & Shel-
drick, 2002). The correct hand for the substructure was
determined using ABS (Hao, 2004) and SHELXE (Sheldrick,
2002). Initial phases were calculated after density modification
using SHELXE (Sheldrick, 2002). 89.48% of the model was
built using ARP/wARP (Perrakis et al., 1999; Morris et al.,
2004).
The resulting structure was used as a starting model in the
MRSAD module (Panjikar et al., 2009) of Auto-Rickshaw in
space group P43212 for further phase improvement, model
completion and refinement. The molecular-replacement step
of the pipeline was skipped. Refinement of the structure was
carried out using CNS (Brünger et al., 1998), REFMAC5
(Murshudov et al., 2011) and phenix.refine (Afonine et al.,
2012) within Auto-Rickshaw. A search for and refinement of
heavy atoms were conducted using Phaser (McCoy et al., 2007)
and MLPHARE (Winn et al., 2011), which identified 13 sites.
Nine sites were subsequently determined to correspond to the
three I atoms from each of three I3C ligands, and four sites
corresponded to the S atoms of two methionine and two
cysteine residues in the structure. Density modification was
performed in Pirate (Cowtan, 2000). Model building was
conducted using SHELXE (Sheldrick, 2002), RESOLVE
(Terwilliger, 1999, 2000) and Buccaneer (Cowtan, 2006), which
collectively built 128 out of 129 residues that were correctly
docked in the electron density. REFMAC5 and phenix.refine
were used to further refine the structure, which resulted in an
R and Rfree of 31.48% and 34.53%, respectively. The structure
was then iteratively rebuilt and refined using Coot (Emsley &
Cowtan, 2004) and phenix.refine to an R and Rfree of 19.67%
and 24.04%, respectively. Structure-solution statistics are
summarized in Table 2.
2.3. Expression of Orf11 NTD
Staphylococcus phage P68 Orf11 N-terminal domain (resi-
dues 2–200) was expressed in Escherichia coli BL21(DE3)
cells carrying the pLysS and pET-15b Orf11 NTD plasmids
(strain JT438). JT438 cells were grown overnight in 5 ml LB
medium supplemented with 100 mg ml1 ampicillin. The cells
were diluted 1:200 into fresh prewarmed LB medium
supplemented with 100 mg ml1 ampicillin. The culture was
grown at 37C with shaking until an OD600 of 0.6 was reached
and were then induced overnight at 16C using isopropyl
-d-1-thiogalactopyranoside (IPTG) at a final concentration
of 200 mM. The cells were harvested by centrifugation at 5000g
for 20 min. The cell pellets were stored at 80C.
2.4. Purification of Orf11 NTD
The cell pellets were thawed and resuspended in START
buffer [20 mM Tris pH 7.6, 500 mM NaCl, 20 mM imidazole,
5 mM -mercaptoethanol (BME) pH 7.2]. Cell resuspensions
were lysed by sonication on ice (5  30 s, 50% duty cycle,
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Table 1
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell.
Protein HEWL Orf11 NTD




Wavelength (Å) 1.459 1.459
Temperature (K) 100 100




Rotation range per image () 1 1
Total rotation range () 360 360
Space group P43212 P3121
a, b, c (Å) 77.16, 77.16, 38.20 61.397, 61.397, 101.606
, ,  () 90, 90, 90 90, 90, 120
Resolution range (Å) 38.20–1.87 (1.92–1.87) 36.73–2.08 (2.13–2.08)
Total No. of reflections 428577 (7041) 267451 (14604)
No. of unique reflections 9810 (475) 13689 (853)
Completeness (%) 98.4 (76.4) 98.3 (80.0)
Multiplicity 43.7 (14.8) 19.5 (17.1)
hI/(I)i 23.0 (1.8) 22.2 (3.5)
Wilson B factor (Å2) 17.501 42.71
Rp.i.m. 0.019 (0.198) 0.013 (0.134)
Rmeas 0.127 (0.850) 0.060 (0.578)
Ranom 0.0777 (0.171) 0.0528 (0.160)
CCanom 0.452 (0.120) 0.291 (0.038)
CC1/2 0.999 (0.938) 1 (0.983)
Table 2
Structure-solution statistics.
Values in parentheses are for the highest resolution shell.
Protein HEWL Orf11 NTD
Molecular mass (kDa) 14.3 22.8
Reflections used in refinement 9547 (921) 13296 (1219)
Reflections used for Rfree 913 (97) 893 (94)
Rwork 0.1967 (0.3442) 0.1792 (0.2498)
Rfree 0.2404 (0.3874) 0.2245 (0.3030)
CCwork 0.948 (0.887) 0.966 (0.910)
CCfree 0.923 (0.778) 0.938 (0.866)





No. of protein residues 129 199
R.m.s.d., bonds (Å) 0.003 0.003
R.m.s.d., angles () 0.54 0.50
Ramachandran favored (%) 99.21 96.95
Ramachandran allowed (%) 0.79 3.05
Ramachandran outliers (%) 0.00 0.00
Rotamer outliers (%) 0.00 2.00
Clashscore 5.39 3.32





No. of TLS groups 5 5
Sonifier Cell Disruptor B-30). The lysate was clarified by
centrifugation at 40 000g for 1 h and subsequent filtration
through 0.45 and 0.2 mm syringe filters (Sartorius Minisart)
using a disposable syringe. The supernatant was subjected to
Ni2+–IMAC chromatography on a 5 ml HisTrap FF column
(GE Healthcare) using an NGC FPLC system (Bio-Rad). The
column was washed with ten column volumes of START
buffer. The protein was eluted from the column with START
buffer with an imidazole gradient from 70 to 220 mM over
eight column volumes, followed by an imidazole gradient from
220 to 500 mM over two column volumes. Fractions showing
UV absorbance A280 above baseline were tested for purity
using SDS–PAGE. Fractions containing the purified protein
were pooled and dialysed against 25 mM Tris pH 7.5, 150 mM
NaCl, 10% glycerol, 5 mM BME. The protein was concen-
trated to 50 mg ml1 using Amicon Ultra-15 centrifugation
units (Millipore) and was stored at 80C.
2.5. Crystallization of Orf11 NTD using the rMMS protocol
in the presence of I3C
Crystallization screening for the Orf11 NTD protein was
conducted at 16C by the sitting-drop vapor-diffusion method
in 96-well Intelli-Plates (Art Robbins) using the commercial
PEG/Ion HT screen (Hampton Research). The stored protein
was diluted to 30 mg ml1 in 25 mM Tris pH 7.5, 150 mM
NaCl, 10% glycerol, 5 mM BME for crystallization. 1 ml
protein solution was added to 1 ml reservoir solution and
equilibrated over 75 ml reservoir solution. Crystals from
condition G12 of PEG/Ion HT were used to generate an
rMMS seed stock, as described by D’Arcy et al. (2007). A 1 M
stock of lithium I3C solution was prepared as described in
Beck et al. (2008). The protein stock was diluted to 30 mg ml1
using heavy-atom buffer (25 mM Tris pH 7.5, 150 mM NaCl,
10% glycerol, 5 mM BME, 50 mM I3C). The protein stock
contained I3C at a final concentration of 20 mM. Sitting-drop
vapor-diffusion trays were set up with the I3C-containing
protein stock. 1 ml protein solution was added to 1 ml reservoir
solution and 0.1 ml seed stock and was equilibrated over 75 ml
reservoir solution. For crystallization screens without I3C, I3C
was omitted from the buffer used to dilute the protein. The
sizes of the crystals used for data acquisition were estimated to
be between 50 and 75 mm. Crystals appeared after one day and
reached their maximum size within a week. If too many
crystals were observed in the drop, the seed stock was diluted
with PEG/Ion HT condition G12 reservoir solution in subse-
quent optimization steps.
Crystals were mounted on cryoloops (Hampton Research),
passed through Paratone (Hampton Research) for cryopro-
tection and flash-cooled in liquid nitrogen for data collection
(Teng, 1990).
2.6. Data collection, structure solution and refinement of
Orf11 NTD
A seeded crystal from condition H3 of PEG/Ion HT grown
in the presence of I3C showed suitable diffraction. A 2.0 Å
resolution SAD data set was collected at a wavelength of
1.459 Å using an ADSC Quantum 210r CCD detector on the
macromolecular beamline MX1 at the Australian Synchrotron
(McPhillips et al., 2002). At this wavelength, iodine has an f 00
and f 0 of 6.3 and 0.13 e, respectively. 360 diffraction images
with 1 oscillation width were collected at a crystal-to-detector
distance of 120 mm. The diffraction data were processed using
XDS (Kabsch, 2010) and scaled with AIMLESS (Evans &
Murshudov, 2013) (Table 1).
The structure was solved using the SAD protocol of Auto-
Rickshaw (Panjikar et al., 2005). The input diffraction data
were prepared and converted for use in Auto-Rickshaw using
programs from the CCP4 suite (Winn et al., 2011). FA values
were calculated using SHELXC (Sheldrick, 2015). Based on
an initial analysis of the data, the maximum resolution for
substructure determination and initial phase calculation was
set to 3.4 Å. Five heavy atoms out of the maximum number of
nine heavy atoms requested were found using SHELXD
(Schneider & Sheldrick, 2002). The correct hand for the
substructure was determined using ABS (Hao, 2004) and
SHELXE (Sheldrick, 2002). Based on the analysis of the hand
of the substructure, the space group of the data was changed
from P3221 to P3121. Initial phases were calculated after
density modification using SHELXE (Sheldrick, 2002).
84.54% of the model was built using ARP/wARP (Perrakis et
al., 1999; Morris et al., 2004).
The resulting structure was used as a starting model in the
MRSAD module (Panjikar et al., 2009) of Auto-Rickshaw in
space group P3121 for further phase improvement, model
completion and refinement. Refinement of the structure was
carried out using CNS (Brünger et al., 1998), REFMAC5
(Murshudov et al., 2011) and phenix.refine (Afonine et al.,
2012) within Auto-Rickshaw. A search for and refinement of
heavy atoms were conducted using Phaser (McCoy et al., 2007)
and MLPHARE (Winn et al., 2011), which identified four sites.
Three sites were subsequently determined to correspond to
the three I atoms from a single I3C, and one site corresponded
to the S atom of a methionine. Density modification was
performed in Pirate (Cowtan, 2000). Model building was
conducted using SHELXE (Sheldrick, 2002), RESOLVE
(Terwilliger, 1999, 2000) and Buccaneer (Cowtan, 2006), which
collectively built 194 out of 207 residues that were correctly
docked in the electron density. REFMAC5 and phenix.refine
were used to further refine the structure, which resulted in an
R and Rfree of 26.75% and 32.27%, respectively. The structure
was then iteratively rebuilt and refined using Coot (Emsley &
Cowtan, 2004) and phenix.refine to an R and Rfree of 17.34%
and 22.64%, respectively. Structure-solution statistics are
summarized in Table 2.
2.7. PDB codes
The coordinates and structure factors for Orf11 NTD and
HEWL have been deposited in the Protein Data Bank as
entries 6o43 and 6pbb, respectively.
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3. Results
3.1. I3C can be added to a random microseed matrix screen
and still give rise to more crystals than unseeded protein
The effect of adding I3C to an rMMS optimization screen
was tested using HEWL as a model crystallization protein.
rMMS optimization has previously been successfully applied
to lysozyme to increase the number of conditions supporting
crystal growth in the JCSG, PACT and Morpheus screens (Till
et al., 2013). Consistent with previous studies, we observe that
rMMS increases the number of conditions in which lysozyme
can crystallize in the Index HT screen (Hampton Research).
The rMMS screen generated 35 more conditions that
supported crystal growth [Fig. 2(a)]. Adding I3C without
seeding to the screen did not notably increase the number of
crystallization conditions found. Eight conditions no longer
research papers
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Figure 2
rMMS can generate new conditions that support the crystal growth of HEWL in the presence of I3C. (a) Crystallization conditions supporting the crystal
growth of HEWL in the Index HT screen are shaded in red. Seed stock was made from lysozyme crystals grown in 0.2 M ammonium tartrate dibasic pH
7.0, 20%(w/v) polyethylene glycol 3350. (b) Representative photographs showing crystals that formed with and without seeding both in the presence and
absence of I3C. (c) Dilution of seed stock was used to reduce the number of seeds to influence the crystal size. Seed stock was diluted 1:10 to give fewer
and larger crystals in condition B12 of Index HT.
supported crystal growth and three new conditions were found
in the presence of I3C. Adding I3C to the lysozyme rMMS
optimization screen generated substantially more conditions
than screens without seeding with and without I3C [Fig. 2(a)].
Having used HEWL as a test case, we tested this technique
with a protein with significantly lower crystallizability, Orf11
NTD.
Only one hit condition was obtained from the initial screen
with Orf11 NTD using the PEG/Ion HT screen (Hampton
Research). This condition generated a shower of microcrystals
that were too small to mount for X-ray diffraction. Adding
I3C to the screen resulted in the same hit condition but gave
no new conditions. The crystalline material from the unseeded
screen was used to make a seed stock for an rMMS screen
using PEG/Ion HT with and without I3C added. Five and six
new crystallization hits were identified in these optimization
screens, respectively [Fig. 3(a)].
The new hit condition H3 from PEG/Ion found by adding
undiluted seed stock produced too many crystals and was
optimized for crystal number by the dilution of seed stock as
detailed in Fig. 2. The growth of fewer crystals resulted in
larger crystals [Fig. 3(c)]. These two screens using HEWL and
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Figure 3
rMMS was used to find new hit conditions that support the crystal growth of Orf11 NTD in the presence of I3C. (a) Crystallization conditions supporting
crystal growth of Orf11 NTD in the PEG/Ion HT screen are colored. The crystallization condition used for seed stock is shown in blue. (b)
Representative photographs showing Orf11 NTD crystals that formed without and with seeding. (c) Dilution of seed stock can reduce excess nucleation
to give larger crystals. Seed stock was diluted 1:10 to give fewer but larger crystals in condition H3 of PEG/Ion HT.
Orf11 NTD provide a proof of concept
that I3C-derivatized crystals can be
grown and optimized using seeding
from a nonderivatized crystal.
To confirm that I3C was incorporated
into the crystals, crystals from the I3C
rMMS screen were harvested and the
crystal structures of the two proteins
were solved using the anomalous signal
without any external template informa-
tion.
3.2. Structure of HEWL
The structure of HEWL was solved
by SAD phasing using diffraction data
from a crystal grown using condition C6
of Index HT [Fig. 4(a)]. The structure
showed four I3C molecules bound to a
single HEWL monomer in the asym-
metric unit, with occupancies of 57, 54,
32 and 26% [Fig. 4(c)]. A structural
superposition of the structure with a
previously solved structure of HEWL
from a crystal co-crystallized with I3C
(PDB entry 3e3d; Beck et al., 2008)
showed that two of the four I3C mole-
cules bind to the same positions in the
protein [Fig. 4(d)].
3.3. Structure of Orf11 NTD
The structure of Orf11 NTD was
obtained by SAD phasing using
diffraction data from a crystal grown
using condition H3 of PEG/Ion HT
[Fig. 3(c)] in an rMMS screen in the
presence of I3C. This structure is shown
in Fig. 5(a), with representative electron
density shown in Fig. 5(b). One I3C
molecule was bound to the protein with
an occupancy of 53% and provided
sufficient signal to phase the structure.
An intrinsic S atom from Met138
provided a fourth anomalous scattering
atom. All scattering atoms displayed
clear density in the anomalous differ-
ence map [Figs. 5(c) and 5(d)].
4. Discussion
4.1. The I3C–rMMS method shows
promise
Molecular-replacement (MR) phasing
is the most popular method for solving
protein structures; however, in many
cases the protein target lacks a suitable
homology or ab initio model for
research papers
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Figure 4
Structure solution of HEWL. (a) The crystal structure of HEWL. (b) Stereoview of a composite
OMIT 2mFo  DFc electron-density map of HEWL. The contour level was set to 1. (c)
Substructure density of each I3C molecule. The anomalous difference map is contoured at 5. The
map was generated using phenix.maps. (d) The crystal structure of HEWL (PDB entry 6pbb) was
superimposed onto a previously solved structure of lysozyme soaked with I3C (PDB entry 3e3d)
and shows that two I3C molecules are bound in the same position.
successful MR phasing. In such cases, experimental phasing is
the method of choice for solving the phase problem. For
proteins that do not intrinsically possess scattering atoms,
external anomalous scatterers can be incorporated into the
crystal by soaking or co-crystallizing the protein with heavy
atoms. If heavy-atom ions or small molecules are incorporated
into a crystal via co-crystallization, it usually results in higher
occupancy. Another benefit of co-crystallization over soaking
is that it reduces manual crystal-manipulation steps that may
damage the crystal.
However, soaking is often preferred over co-crystallization
to derivatize crystals. Co-crystallization requires the set up of
additional screens. In addition, attempting to co-crystallize a
heavy-atom ligand in the same condition that yields
underivatized crystals can fail to yield crystals. This observa-
tion is unsurprising as the ligand can change the equilibrium of
the crystallization condition or the crystal contacts (Garman &
Murray, 2003; McPherson & Cudney, 2014). In this study, we
present an efficient method for screening for crystallization
conditions that co-crystallize a phasing compound into a
protein crystal.
rMMS often substantially increases the number of hit
conditions and produces improved diffraction-quality crystals
in new crystallization conditions (D’Arcy et al., 2007; Obmo-
lova et al., 2010). I3C has previously been demonstrated to
bind to proteins within a protein crystal, often via multiple
functional groups. The amino group and carboxyl groups of
I3C can form hydrogen bonds directly to the protein backbone
and side chains or via water bridges to
the protein. The benzene ring and
iodine allow – interactions and
halogen bonds, respectively. The ability
to form multiple interactions results in
I3C binding with high specificity and
occupancy in a protein crystal (Beck et
al., 2008).
It is possible that I3C can also stabi-
lize a lattice and/or generate new crystal
contacts, resulting in a protein crystal
with improved mechanical and diffrac-
tion properties. In the HEWL crystal,
three of the four I3C molecules interact
with three different protein monomers
[Fig. 6(a)]. In the Orf11 NTD crystal,
I3C was found at the interface between
three Orf11 NTD molecules and makes
interactions with all three protein
molecules [Fig. 6(b)]. Such contacts
between the protein molecules bridged
by I3C may explain why this crystal-
lization condition was only found when
rMMS was combined with I3C and not
with rMMS alone. We are aware of one
published case in which protein crystals
would only form in the presence of I3C
and would fail without it (Leverrier et
al., 2011). Thus, it seems likely that I3C
can increase the number of hits found
by rMMS by creating new crystal
contacts. In this study, a small increase
in the number of hits was found by
adding I3C to rMMS over a standard
rMMS screen. However, this is not a
clear positive effect as some hit condi-
tions were lost upon adding I3C.
By adding I3C to the protein solution
and using rMMS, we are efficiently
searching for crystallization conditions
in which I3C can bind the protein.
rMMS increases the likelihood of
obtaining crystals, and any such protein
research papers
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Figure 5
Structure solution of Orf11 NTD. (a) The crystal structure of Orf11 NTD. (b) Stereoview of a
composite OMIT 2mFoDFc electron-density map of Orf11 NTD. The contour level was set to 1.
Substructure density of I3C and the intrinsic S atom are shown in (c) and (d), respectively. The
anomalous difference map is contoured at 5. The map was generated using phenix.maps.
crystals obtained are likely to have I3C
incorporated, ready for SAD phasing.
This approach has successfully been
applied to both the HEWL and Orf11
NTD proteins. In both cases, an increase
in the number of hit conditions was
identified in the rMMS with I3C screens
compared with the unseeded screens
with and without I3C. For both HEWL
and Orf11 NTD, one of these new
conditions was confirmed to produce
I3C-derivatized crystals that allowed
solution of the protein structure.
There are several benefits to the use
of I3C with rMMS screening compared
with many of the compounds that are
commonly used for derivatization.
Firstly, I3C is inexpensive and readily
available. Secondly, many of the
commonly used heavy-metal salts such
as uranyl acetate and platinum potas-
sium chloride are incompatible with our
rMMS approach. Many of these metal
ions will form insoluble compounds
when mixed with sulfate and phosphate
buffers. Citrate and acetate in certain
crystallization conditions can also
chelate divalent metal ions to reduce
their effective concentration (Pike et al.,
2016). Sulfate, phosphate, citrate and
acetate are all commonly used in
crystallization conditions and would
preclude many heavy metals from our
rMMS approach. Finally, some heavy
atoms, but not I3C, react with HEPES
and Tris and/or bind to DTT and
-mercaptoethanol, which are used in
many protein preparations (Pike et al.,
2016).
I3C intrinsically provides two benefits
when solving structures. Each I3C
molecule provides three heavy scat-
tering atoms, providing a significant
anomalous signal for phasing. The
heavy atoms are arranged in an equi-
lateral triangle with sides of 6 Å. This
arrangement allows the presence of I3C
to be confirmed in the substructure-
determination stage. If a triangle with
these dimensions is found, it indicates a
correct substructure. The specificity of
I3C binding also makes it preferable to
halide or alkali metal ions, which bind to
many positions on the protein. This lack
of specificity can result in many poorly
occupied sites, making substructure
determination difficult.
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Figure 6
I3C can mediate contacts between protein molecules in a crystal. One I3C molecule from (a) the
HEWL crystal and (b) the Orf11 NTD crystal are shown. The same I3C molecule from the Orf11
NTD crystal is displayed in two different orientations for clarity. I3C–protein interactions include
hydrogen bonding, – stacking interactions, salt bridges, water bridges and halogen bonding. In
both cases, each I3C molecule forms interactions with three different protein molecules (each
shown in a different color), which could assist in lattice packing. Protein–ligand interaction analysis
was conducted using the PLIP web server (Salentin et al., 2015).
Figure 7
Orf11 is predicted to have a GyH domain and a CHAP domain, connected via a linker containing
three -helices. This predicted domain architecture of Orf11 is similar to that of the endolysin
protein PlyCA from Streptococcus phage C1. The PlyCA domain architecture was defined using the
crystal structure of the protein (PDB entry 4f88; McGowan et al., 2012). The domain architecture of
Orf11 was assigned using multiple bioinformatics tools. The GyH domain was identified using the
FFAS-3D homology-detection server (Xu et al., 2014). The CHAP domain was determined using
the Pfam protein-domain database (Finn et al., 2016). The -helical content within the linker region
was defined using the JPred4 secondary-structure prediction server (Drozdetskiy et al., 2015). The
residue numbers for the domain boundaries are annotated above the diagrams.
Another benefit of using iodine is that it provides a large
anomalous signal (f 00 = 6.9 e) at the Cu K wavelength used by
many home-source X-ray generators (and can also be used on
home sources for isomorphous replacement). This property
would allow the collection of anomalous data for phasing
without the need to wait for synchrotron beamtime.
This screening approach can be applied to identify new co-
crystallization conditions using other heavy-atom molecules.
One possibility is the MAD triangle (Beck et al., 2010), which
has a similar molecular structure with iodine substituted by
bromine. This phasing molecule has the benefit of allowing
MAD phasing as the Br K edge is accessible at many
research papers
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Figure 8
Orf11 shows limited sequence similarity and high structural similarity to the PlyCA protein from Streptococcus phage C1. (a) Sequences of the PlyCA
GyH domain (residues 1–213) and the Orf11 NTD domain (residues 1–201) were aligned using T-Coffee (Armougom et al., 2006), with an identity of
22% and a sequence similarity of 40%. Alignments were displayed using ESPript (Gouet et al., 1999) and similarity was calculated using the Risler matrix
(Risler et al., 1988). (b) A superposition of the PlyCA GyH domain and Orf11 NTD structures shows that the proteins adopt similar tertiary folds. The
two proteins were superimposed with PyMOL (DeLano, 2002) using C positions, with an r.m.s.d. of 3.5 Å over 127 atoms. (c) The conserved catalytic
residues of the glucosaminidase domain of GyH are Glu78, Tyr74 and Asn87. The equivalent residues Glu71, Tyr67 and Asn81 in Orf11 NTD appear in
similar positions. The residues appear in an electronegative cleft in the protein. The electrostatic potentials of Orf11 NTD were calculated using the
APBS plugin in PyMOL.
synchrotron beamlines. It would also be of interest to test
the tantalum bromide cluster (Knäblein et al., 1997), which
provides an extremely large amount of phasing power, espe-
cially for large proteins or protein–protein/DNA complexes.
4.2. Orf11 is likely to be a lysin
Bacteriophage P68 Orf11 was identified as a putative
endolysin using a bioinformatics approach. Endolysins are
enzymes that degrade the peptidoglycan structure in bacterial
cell walls and, along with holins that form pores in the inner
membrane, form the escape system for bacteriophages to exit
their host via lysis (Young, 2014). A homology search using
the FFAS (Xu et al., 2014) and Pfam (Finn et al., 2016) web
servers identified two putative domains in the Orf11 protein:
an N-terminal glycosyl hydrolase (GyH) domain and a
C-terminal cysteine, histidine-dependent aminohydrolase/
peptidase (CHAP) domain (Fig. 7). Both domains commonly
appear in endolysin proteins (Oliveira et al., 2013). Another
possibility is that Orf11 corresponds to a virion-associated
lysin protein (VAL). Some phages, particularly those that
infect Gram-positive bacteria, use glycosyl hydrolases asso-
ciated with the virion to degrade the peptidoglycan layer
(Fernandes & São-José, 2018). This process clears a path to
enable the phage to find the cell membrane and allows the
phage machinery to inject DNA into the cell.
The structure of Orf11 NTD is very similar to that of the
GyH domain of PlyC. PlyC is an endolysin protein from
Streptococcus phage C1 and is the most potent endolysin
protein discovered to date (McGowan et al., 2012; Riley et al.,
2015). PlyC consists of one PlyCA polypeptide mounted on
a PlyCB octamer. A structural superposition of the GyH
domain of PlyCA (PDB entry 4f88; McGowan et al., 2012)
with Orf11 NTD reveals similar overall folds, despite a low
sequence identity between the domains of 22% [Figs. 8(a) and
8(b)]. However, attempts to solve the data set via molecular
replacement using the PlyC GyH domain as a model failed to
yield a solution. Small deviations from the true structure in the
template may have prevented the algorithm from finding an
initial solution. The glycosyl hydrolase domain of PlyCA has
three key catalytic residues, Glu78, Tyr74 and Asn87, thought
to form the catalytic center. In the structure of Orf11 NTD
these same residues appeared at similar spatial positions
within an electronegative cleft in the protein [Fig. 8(c)]. From
this, it is possible that the Orf11 NTD is a glycosyl hydrolase.
A secondary-structure prediction of Orf11 shows that a
region containing three -helices lies between the two
domains (Fig. 7). This topology is similar to that of PlyCA,
which has a helical docking domain consisting of three
-helices that anchors it to the cell-wall-binding protein PlyCB.
All of this, taken together, suggests that Orf11 is a lysin
protein that perhaps requires an additional protein to direct it
to its bacterial target.
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